SCHEMBL1429007

SCHEMBL1429007

COC(=O)CC(c1ccccc1)c1ccc(OC)c(S(=O)(=O)N=C(N)N)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4D Q08499 4/20 0.43
▸ PDE4A P27815 3/20 0.43
▸ PDE4B Q07343 3/20 0.43
▸ PDE4C Q08493 3/20 0.43
▸ TNF P01375 3/20 0.43
▸ F2 P00734 3/20 0.42
▸ PRSS1 P07477 3/20 0.42
▸ PRSS2 P07478 3/20 0.42
▸ PRSS3 P35030 3/20 0.42
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ALDH1A1 P00352 6/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HPGD P15428 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1428456 0.91 F2 (0.43) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL1428480 0.84 ALDH1A1 (0.46) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL1428388 0.83 ALDH1A1 (0.45) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL4825769 0.76 PDE4D (0.64) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL2347309 0.72 HPGD (0.57) ALDH1A1HPGDMAPTKMT2ALMNA
SCHEMBL29184115 0.72 TNF (0.59) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL2890299 0.72 TNF (0.47) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL4822203 0.71 PDE4A (0.68) PDE4DPDE4APDE4BPDE4C
SCHEMBL29883153 0.70 TNF (0.60) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL29174154 0.70 TNF (0.60) PDE4DPDE4APDE4BPDE4CTNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300010-B1 PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS NOVARTIS AG (CH) 2015-03-04 — — EP disclosed
US-8236808-B2 Pyrazine derivatives as ENAC blockers NOVARTIS AG (CH) 2012-08-07 — — US disclosed
US-20110201625-A1 Organic Comopunds NOVARTIS AG (CH) 2011-08-18 — — US disclosed
EP-2300010-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2011-03-30 — — EP disclosed
WO-2009150137-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201625-A1 Organic Comopunds OR10J3, CFTR, CLIC1 PDE4D 2904/4885PDE4A 2350/4885PDE4B 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback